



Crescendo Biologics nominated for Mediscience Emerging Star Award

Cambridge, UK, 9 May 2017 – Crescendo Biologics Limited (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces it has been nominated for the European Mediscience Emerging Star Award.

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies. The Emerging Star Award will be given to a private or young public mediscience company that has demonstrable credibility in terms of business model/strategy, management team and financing.

Crescendo is nominated for its transition from a technology platform company to a developer of Humabody® therapeutics. The company has created a rich internal pipeline of truly differentiated, multi-functional biologics with a focus on oncology. The company's innovative approach was validated last October through a commercial partnership with Takeda worth US\$790m.

The other nominees in the category are:

- AiCuris GmbH & Co. KG
- Artios Pharma Ltd
- Blue Earth Diagnostics Ltd
- F-star Biotechnology Ltd
- PsiOxus Therapeutics Ltd
- Quanta Dialysis Technologies Ltd

Details of the awards dinner and ceremony are as follows:

16th European Mediscience Awards 2017

Date: Thursday 15 June 2017

Time: 19:00

Location: The Brewery, 52 Chiswell St, London, EC1Y 4SD

For more information on Crescendo or for media enquiries, please contact crescendo@instinctif.com.

Ends



For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel:44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell	Tel:44 (0)20 7457 2020 crescendo@instinctif.com

Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated mono- and multi-functional Humabody[®] therapeutics in oncology. The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody[®] V_H) with superior biophysical properties and developability.

Crescendo is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com .

About Humabody[®] Therapeutics

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V_H domain building blocks (Humabody[®] V_H) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies offer a unique combination of potential benefits resulting from their small size, cost-effective production and robust biophysical properties. These attributes allow Crescendo to optimally configure an almost limitless range of multifunctional Humabody[®] formats in a rapid timeframe.

Crescendo is developing a pipeline of novel, Humabody[®]-based therapeutics in oncology. Its next-generation mono- and multi-specific Humabody[®] immune-oncology modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response, as well as enhancing



antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Its Humabody® Drug Conjugates (HDCs) deliver a superior therapeutic index to standard ADCs.

For more information, please visit the website: www.crescendobiologics.com/humabody/.

About the event

The European Mediscience Awards is now in its 16th year, having been held every year since inception in 2002.

The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, it is the must-attend event for anybody working in this sector.

Each year sees the attendance of over 500 quoted and private European life science companies and their corporate advisers, analysts, fund managers, commentators and peers.

The event is sold out from one year to the next. The 2017 European Mediscience Awards will take place on Thursday 15 June at the Brewery, London EC1.

For more information, please visit the website: <http://www.mediscience-event.co.uk/>